Results 241 to 250 of about 87,999 (333)

Combined Inhibition of TRPM4/NMDA Receptor Complex and Extrasynaptic NMDA Receptors Is Candidate Therapeutic Target for Suppression of Epileptic Seizures and Improvement of Cognitive Impairments

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Cognitive impairments are important therapeutic targets in epilepsy medication; however, effective pharmacological treatments for epilepsy patients with comorbid cognitive impairment have not been established. Effects of chronic administration of MK‐801 (noncompetitive NMDA receptor inhibitor), memantine (low‐affinity extrasynaptic‐NMDA ...
Motohiro Okada   +3 more
wiley   +1 more source

Effects of prematurity and socio‐economic status on early life language exposure: A video coding study

open access: yesBritish Journal of Developmental Psychology, Volume 44, Issue 2, Page 469-484, June 2026.
Abstract Preterm birth is associated with later language impairment and delay. Socio‐economic deprivation is linked to decreased language exposure in early childhood, but it is unknown how prematurity influences this relationship. This study investigated the effects of socio‐economic status and gestational age at birth on language exposure, in a sample
Sinéad O'Carroll   +5 more
wiley   +1 more source

Induction of IL‐9‐producing CD8+ T cells by ascochlorin derivatives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 11, Page 3015-3031, June 2026.
A newly synthesised ascochlorin derivative, N184, induces small amounts of IL‐9‐producing CD8+ T cells. N184 improved the survival of CD8+ T cells and enhanced their antitumour activity, partially in an IL‐9‐dependent manner. The antitumour effect was completely dependent on IFNγ secretion rather than the cytotoxic activity of CD8+ T cells.
Natsumi Imano   +5 more
wiley   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 11, Page 2660-2674, June 2026.
Abstract Background and Purpose Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single‐rising‐dose Phase I study in healthy volunteers and in a combined single‐ and multiple‐rising‐dose Phase Ib study in patients with mild asthma ...
Saskia Carstensen‐Aurèche   +8 more
wiley   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy